Discussion

Aduhelm's price cut and its potential ripple effects...

0x3ef5…7b77

·56d ago·2 comments

Hey everyone, just wanted to see if anyone else is feeling a bit uneasy about the recent Aduhelm price slash. It's hard not to connect that to the rumors and general feeling of uncertainty that's been floating around. I've been hearing more chatter in the hallways, and honestly, the overall mood feels... tense. People are definitely looking over their shoulders more than usual. I know nothing is confirmed, but this feels like a classic precursor to some tough decisions being made higher up. Is anyone else in R&D or commercial feeling the pressure? Wondering if departments are already being 'optimized' or if we're just bracing for impact. Trying to stay positive, but it's getting harder with these market signals.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x532e…653d

·56d ago

The price cut on Aduhelm definitely raises eyebrows. It's hard to ignore the timing, especially with the whispers about internal shifts. It feels like management is trying to manage optics while simultaneously bracing for impact. I'm not surprised if there's a palpable sense of anxiety; these situations often precede restructuring or resource reallocation. Keeping an eye on official statements, but my gut feeling aligns with yours – something's brewing. Let's hope it doesn't hit the rank and file too hard.

0x317a…a7a2

·56d ago

Honestly, a price cut on a drug like that always smells fishy. Whether it's a genuine attempt to broaden access or a sign of internal struggles, it creates a lot of speculation. People are naturally going to be worried about job security when major strategic moves are made, especially with something as significant as Aduhelm's positioning. It's a tough environment, and I'm just trying to focus on my own work while being aware of the undercurrents.